Mycobax Market Report 2026

Mycobax Market Overview

• The Mycobax market growth in the historic period has been driven by increasing incidence of non-tuberculous mycobacterial infections, limited effectiveness of conventional antibiotic therapies • Market expansion is supported by increasing investment in novel immunotherapies, growing demand for alternatives to long-term antibiotics • Growth Driver: Rising Tuberculosis Incidence Driving Growth Of The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Mycobax Market?

Mycobax is an investigational vaccine based on bacillus calmette-guérin (BCG) and is designed to serve as an immunotherapy for managing non-tuberculous mycobacterial (NTM) infections. The vaccine works by modulating the immune system, enhancing the body's ability to fight chronic and often drug-resistant lung infections. These infections are particularly prevalent among individuals with underlying conditions such as bronchiectasis or cystic fibrosis. The main indications for mycobax are tuberculosis prevention and post-exposure prophylaxis. Tuberculosis prevention refers to the use of medical interventions, such as vaccines or treatments, to stop the spread of tuberculosis (TB). This is available in various formations, such as injectable solution and lyophilized powder for reconstitution, and distributed through hospitals, public health clinics, pharmacies, and mobile vaccination units and used by infants and children, and adults.

What Is The Mycobax Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investment in novel immunotherapies, growing demand for alternatives to long-term antibiotics, expansion of personalized infection management, rising clinical trial activity for ntm vaccines, increasing focus on immune-based disease control. Major trends in the forecast period include increasing development of immunomodulatory therapies for ntm infections, rising focus on chronic lung disease management, growing interest in bcg-based immunotherapies, expansion of investigational vaccine pipelines, enhanced emphasis on treatment for drug-resistant infections.

Global Mycobax Market Segmentation

1) By Indication: Tuberculosis Prevention, Post-Exposure Prophylaxis 2) By Formulation: Injectable Solution, Lyophilized Powder For Reconstitution 3) By Distribution Channel: Hospitals, Public Health Clinics, Pharmacies, Mobile Vaccination Units 4) By End-User Patients: Infants And Children, Adults

What Are The Drivers Of The Mycobax Market?

The growing incidence of tuberculosis is expected to drive the growth of the mycobax market going forward. Tuberculosis is a highly contagious infectious disease caused by mycobacterium tuberculosis, primarily affecting the lungs but potentially impacting other parts of the body. The growing incidence of tuberculosis is attributed to factors such as overcrowding, poor sanitation, rising HIV co-infections, and the emergence of multidrug-resistant (MDR) TB strains. Mycobax is designed to provide more effective immunity against mycobacterium tuberculosis, particularly in regions with high TB transmission where BCG's effectiveness is limited. For instance, in March 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, the number of tuberculosis cases rose from 8,320 in 2022 to 9,615 in 2023, reflecting an increase of 1,295 cases. Therefore, the growing incidence of tuberculosis is driving the growth of the mycobax industry. The increasing healthcare infrastructure is expected to propel the growth of the mycobax market going forward. Healthcare infrastructure encompasses the key physical facilities, resources, and systems required to deliver quality healthcare, such as hospitals, clinics, medical equipment, and trained healthcare professionals. The increasing healthcare infrastructure is driven by several factors, including a rising global population, an aging demographic, and rapid urbanization. With the expansion of healthcare infrastructure, Mycobax can seamlessly integrate into emerging vaccination programs in high-risk regions, offering a powerful preventive tool to mitigate the tuberculosis (TB) burden. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the United States had 6,129 hospitals, representing a 0.591% increase from the previous year when there were 6,093 hospitals. Therefore, the increasing healthcare infrastructure is driving the growth of the mycobax industry. The surge in the number of newborn babies is expected to propel the growth of the mycobax market going forward. The global baby population is rising due to improved healthcare, reduced infant mortality, and high birth rates in certain regions. Mycobax is designed for safe and effective tuberculosis (TB) prevention in infants, providing early protection in vulnerable populations. For instance, in July 2024, according to database.earth, a US-based data visualization/web tool platform, it was reported that in the year 2025, a total of 132,399,173 babies will be born across the globe. Out of this group, 34,085,338 were male and 29,050,646 were female. Therefore, the surge in the number of newborn babies is driving the growth of the mycobax industry.

Key Players In The Global Mycobax Market

Major companies operating in the mycobax market are Sanofi Pasteur Ltd.

Regional Insights

North America was the largest region in the mycobax market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Mycobax Market?

The mycobax market consists of the sales of mycobax detection systems, mycobax polymerase chain reaction (PCR) kits, and mycobax environmental testing kits. Values in this market are ‘factory gate’ values, representing the value of goods sold by manufacturers directly to other entities (such as downstream manufacturers, wholesalers, distributors, retailers, or end customers). The market value includes related services provided by the vaccine developers.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Mycobax Market Report 2026?

The mycobax market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the mycobax industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.